Delving into the Latest Updates on Xingji Biology (Suzhou) Co., Ltd with Synapse

Overview

Tags

Infectious Diseases

Other Diseases

Antibody

Protein drugs

Fusion protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	8

Top 5 Drug Type	Count

Antibody	4
Biological products	1
Fusion protein	1
Monoclonal antibody	1
Protein drugs	1

I期临床试验主要目的：评价XJ106-1注射液单次肌肉注射在健康成年参与者中的安全性和耐受性。 I期临床试验次要目的：研究单次肌肉注射XJ106-1注射液在健康成年参与者中的药代动力学（PK）特征；评价单次肌肉注射XJ106-1注射液在健康成年参与者中预防破伤风的免疫原性；评价单次肌肉注射XJ106-1注射液在健康成年参与者中预防破伤风的PK/PD特征。 II期临床试验主要目的：比较XJ106-1注射液与破伤风人免疫球蛋白（HTIG）在健康人群中预防破伤风的有效性；探索XJ106-1注射液单次肌肉注射预防破伤风的临床给药剂量。 II期临床试验次要目的：评价单次肌肉注射XJ106-1注射液与吸附破伤风疫苗（TT）联合用药的安全性、耐受性、药代动力学（PK）和药效学（PD）；评价XJ106-1注射液单次肌肉注射在健康成年参与者中的安全性和耐受性；研究单次肌肉注射XJ106-1注射液在健康成年参与者中的药代动力学（PK）特征；评价单次肌肉注射XJ106-1注射液在健康成年参与者中预防破伤风的免疫原性。

[Translation]

The primary objective of the Phase I clinical trial was to evaluate the safety and tolerability of a single intramuscular injection of XJ106-1 injection in healthy adult participants. Secondary objectives of the Phase I clinical trial were to investigate the pharmacokinetic (PK) characteristics of a single intramuscular injection of XJ106-1 injection in healthy adult participants; to evaluate the immunogenicity of a single intramuscular injection of XJ106-1 injection for tetanus prevention in healthy adult participants; and to evaluate the PK/PD characteristics of a single intramuscular injection of XJ106-1 injection for tetanus prevention in healthy adult participants. The primary objective of the Phase II clinical trial was to compare the efficacy of XJ106-1 injection with human tetanus immunoglobulin (HTIG) in preventing tetanus in healthy individuals; and to explore the clinical dosage of a single intramuscular injection of XJ106-1 injection for tetanus prevention. Secondary objectives of the Phase II clinical trial: To evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single intramuscular injection of XJ106-1 in combination with adsorbed tetanus vaccine (TT); To evaluate the safety and tolerability of a single intramuscular injection of XJ106-1 in healthy adult participants; To investigate the pharmacokinetic (PK) characteristics of a single intramuscular injection of XJ106-1 in healthy adult participants; To evaluate the immunogenicity of a single intramuscular injection of XJ106-1 in preventing tetanus in healthy adult participants.

Start Date20 Apr 2026

Sponsor / Collaborator

Xingji Biopharmaceutical (Beijing) Co., Ltd.

NCT06026748

/ Unknown statusPhase 1

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of XJ103 in Chinese Healthy Subjects

This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria. Subjects will be assigned to one of four different dosage cohorts. Subjects in each cohort will randomly be given experimental drug or a placebo.

Start Date12 Sep 2023

Sponsor / Collaborator

Xinyao Biology (Shanghai) Co., Ltd.

NCT06014736

/ Unknown statusPhase 1

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of XJ101 in Chinese Healthy Subjects

This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria. Subjects will be assigned to one of four different dosage cohorts. Subjects in each cohort will randomly be given experimental drug or a placebo.

Start Date15 Aug 2023

Sponsor / Collaborator

Xinyao Biology (Shanghai) Co., Ltd.

100 Clinical Results associated with Xingji Biology (Suzhou) Co., Ltd

Login to view more data

0 Patents (Medical) associated with Xingji Biology (Suzhou) Co., Ltd

Login to view more data

100 Deals associated with Xingji Biology (Suzhou) Co., Ltd

Login to view more data

100 Translational Medicine associated with Xingji Biology (Suzhou) Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

4

1

Preclinical

Phase 2

3

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

XJ103	Pneumococcal Infections More	Phase 2
XJ106-1	Tetanus More	IND Approval
XJ-101	MRSA - Methicillin resistant Staphylococcus aureus infection More	IND Approval
XJ104	Candidiasis More	Preclinical
Antigen-binding protein targeting S.Aureus α-Hemolysis(Xingji Biology)	Bacteremia More	Discovery